sofosbuvir/velpatasvir
Brand names: Epclusa
Vosevi is a drug that combines three medicines into one tablet. It is used to treat hepatitis C in adults who have already tried other treatments.
Drug Pricing (NADAC)
Brand Price
$862.51/unit
Generic Available
No
GILEAD SCIENCES INC
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Vosevi treats chronic hepatitis C (HCV) infection in adults.
Common side effects
Headache, Fatigue (feeling tired), Diarrhea
Key warnings
Vosevi can cause Hepatitis B to become active again if you have had it in the past.
How It Works
Vosevi contains sofosbuvir, velpatasvir, and voxilaprevir. Sofosbuvir blocks a protein called NS5B polymerase that the hepatitis C virus needs to multiply. Velpatasvir blocks the NS5A protein, and voxilaprevir blocks the NS3/4A protease protein, both of which the virus also needs.
How to Take It
Take one Vosevi tablet once a day with food. The tablet contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir. You will likely take Vosevi for 12 weeks. Follow your doctor's instructions carefully.
Pregnancy & Breastfeeding
It is not known if Vosevi can harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Vosevi passes into breast milk, so discuss this with your doctor if you are breastfeeding.
Missed Dose
If you miss a dose of Vosevi, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and take your next dose at the regular time.
Storage
Store Vosevi tablets below 86°F (30°C) in the original container.
Side Effects (from patient reports)
Based on 14,368 FDA adverse event reports.
Serious Warnings
Vosevi can cause Hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Before starting Vosevi, your doctor will test you for Hepatitis B. They will also monitor you during and after treatment.
Known Drug Interactions
Antimycobacterials: rifampin ↓ sofosbuvir ↓ velpatasvir ↑ voxilaprevir (single dose) ↓ voxilaprevir (multiple dose) Coadministration with rifampin is contraindicated [see Contraindications (4) ].
Mechanism: Rifampin causes your body to process the hepatitis C medicine too quickly, which lowers the amount of medicine in your blood.
What to do: You should not take these two drugs together because the hepatitis C treatment will likely fail.
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Mechanism: This hepatitis C medication can increase the amount of rosuvastatin that stays in your blood.
What to do: If you take these together, start with a low 5 mg dose of rosuvastatin and do not take more than 10 mg per day.
Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dose of rosuvastatin 10 mg once daily.
Mechanism: This antiviral medicine increases the amount of rosuvastatin in your system by changing how your body processes it. Higher levels of the drug can increase the risk of muscle damage.
What to do: You should start with a low 5 mg dose of rosuvastatin and never take more than 10 mg daily while using this combination.
HMG-CoA Reductase Inhibitors: pravastatin ↑ pravastatin Coadministration of VOSEVI with pravastatin has been shown to increase the concentration of pravastatin, which is associated with increased risk of myopathy, including rhabdomyolysis. Pravastatin may be administered with VOSEVI at a dose that does not exceed pravastatin 40 mg.
Mechanism: This medication increases the amount of pravastatin that stays in your blood, which makes muscle injury more likely.
What to do: If you take these medicines together, do not take more than 40 mg of pravastatin each day.
Coadministration of VOSEVI with BCRP substrates (e.g., methotrexate, mitoxantrone, imatinib, irinotecan, lapatinib, rosuvastatin, sulfasalazine, topotecan) is not recommended [see Clinical Pharmacology (12.3) ].
Mechanism: This medication can block a specific protein that helps move methotrexate out of your body, which may lead to higher levels of methotrexate in your system.
What to do: Taking these two drugs together is not recommended. Your doctor may need to choose a different medication for you.
Common Questions
Can I take Vosevi if I have kidney problems?
Can I take Vosevi if I have liver problems?
What should I tell my doctor before starting Vosevi?
Can Vosevi interact with other medications?
What if I experience side effects while taking Vosevi?
Can I drink alcohol while taking Vosevi?
How will I know if Vosevi is working?
Is there a cure for hepatitis C?
What happens if I stop taking Vosevi early?
Are there any foods I should avoid while taking Vosevi?
What are the common side effects of sofosbuvir/velpatasvir?
Does sofosbuvir/velpatasvir interact with other medications?
What drug class is sofosbuvir/velpatasvir?
Is sofosbuvir/velpatasvir safe during pregnancy?
Related Medications in NS5B/NS5A Inhibitor (HCV)
Other drugs grouped near sofosbuvir/velpatasvir — same-class peers and common alternatives.
acyclovir
Zovirax
Acyclovir is an antiviral medicine.
Compare with sofosbuvir/velpatasvir →
albendazole
Albenza
Albendazole is a medicine that fights parasites.
Compare with sofosbuvir/velpatasvir →
amphotericin B
Ambisome, Fungizone
Amphotericin B liposome is an antifungal medicine.
Compare with sofosbuvir/velpatasvir →
anidulafungin
Eraxis
Eraxis is an antifungal medicine.
Compare with sofosbuvir/velpatasvir →
atovaquone/proguanil
Malarone
Malarone is a drug used to prevent and treat malaria.
Compare with sofosbuvir/velpatasvir →
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
Why some drugs demand precise dosing and monitoring
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Related Health & Safety Data
🩺 Find a Doctor
Search prescribers for NS5B/NS5A Inhibitor (HCV)
🏨 Hospital Quality
CMS hospital ratings, safety scores & patient outcomes
💊 Supplement Data
NIH DSLD — check supplement ingredients & label claims
🍽️ Food Safety Alerts
FDA recalls, inspections & outbreak investigations
⚠️ Product Recalls
FDA, CPSC & NHTSA recall search
💉 Procedure Costs
Medicare procedure pricing for 9,297 procedures
Save on sofosbuvir/velpatasvir
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for sofosbuvir/velpatasvir
The FDA label for sofosbuvir/velpatasvir (sold under brand names such as Epclusa) classifies it as a prescription-only medication in the NS5B/NS5A Inhibitor (HCV) class. Vosevi treats chronic hepatitis C (HCV) infection in adults. Official labeling lists 4 commonly reported side effects, including Headache, Fatigue (feeling tired), Diarrhea.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 14,368 voluntary reports. The database also lists 33 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated major severity. NADAC pricing from CMS.
Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.
Last updated: July 14, 2025
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- FDA Orange Book — approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed — NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) — post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm — standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files — federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database — current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages